



06-28-04

IFW

Express Mail Label No. EV334240309US

PATENT
Attorney Docket No. RBN-001DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keene et al.
SERIAL NO.: 10/629,453 GROUP NO.: 1645
FILING DATE: July 29, 2003 EXAMINER: Not yet assigned
TITLE: METHODS FOR ISOLATING AND CHARACTERIZING
ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non U.S. patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.


It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,


Christine C. Vito
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: June 25, 2004
Reg. No. 39,061

Tel. No.: (617) 248-7368
Fax No.: (617) 248-7100



TRANSMITTAL FORM

Application Serial Number	10/629,453
Filing Date	July 29, 2003
First Named Inventor	Keene
Group Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket No.	RNB-001DV
Patent No.	Not applicable
Issue Date	Not applicable


ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input checked="" type="checkbox"/> Supplemental Form PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
--	---	--

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
 Testa, Hurwitz & Thibault, LLP
 125 High Street
 Boston, MA 02110
 Tel. No.: (617) 248-7000
 Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

 Date: June 25, 2004
 Reg. No. 39,061
 Tel. No.: (617) 248-7368
 Fax No.: (617) 248-7100
 Christine C. Vito
 Attorney for the Applicants
 Testa, Hurwitz & Thibault, LLP
 125 High Street
 Boston, MA 02110



Express Mail Label No. EV334240309US

FORM PTO - 1449

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

ATTORNEY DOCKET NO.: RBN-001DV

APPLICANTS: Keene et al.

SERIAL NO.: 10/629,453

FILING DATE: July 29, 2003

GROUP: 1645

U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Place of Publication, Relevant Pages, Date)							
	C45	Chen et al., "RNA-Protein Interactions: Involvement of NS3, NS5, and 3' Noncoding Regions of Japanese Encephalitis Virus Genomic RNA," Journal of Virology, Vol. 17, No. 5, pp. 3466-3473, May 1997.						
	C46	Tamanini et al. "Oligomerization Properties of Fragile-X Mental-Retardation Protein (FMRP) and the Fragile-X-Related Proteins FXR1P and FXR2P," Biochem., Vol. 343, pp. 517-523, 1999.						
	C47	Tillmar et al., "Hypoxia May Increase Rat Insulin mRNA Levels by Promoting Binding of the Polypyrimidine Tract-Binding Protein (PTB) to the Pyrimidine-Rich Insulin mRNA-3'-Untranslated Region," Molecular Medicine, 8(5), pp. 263-272, 2002.						
	C48	Wurtz et al., "Identification of Two RNA-Binding Proteins in Balbiani Ring Premessenger Ribonucleoprotein Granules and Presence of These Proteins in Specific Subsets of Heterogeneous Nuclear Ribonucleoprotein Particles," Molecular and Cellular Biology, Vol. 16, No. 4, pp. 1425-1435, April 1996.						
	C49	International Search Report PCT/US03/38475, May 13, 2004, 6 pages.						

EXAMINER**DATE CONSIDERED**

VITO\91992.3076495_1